Chemokine CXCL10 In Children Autoimmunity Thyroid Disease

Objective:To observe the change of serum chemokine CXCL10 in children with AITD including Graves' Disease.(GD) and Hashimotos thyroiditis(HT) when they were in different course of disease.To study the relationship between the level of serum chemokine CXCL10 and the level of function of thyroid(FT3,FT4,sTSH) and the relationship between the level of serum chemokine CXCL10 and the level of thyroid antibody(TGAb,TMAb,TRAb,TSI),and then explore the role of chemokine CXCL10 in children with AITD when they were inatial stage and different course.Methods:The children AITD cases of Tianjin medical university hospital pediatric endocrine clinic and their serum were random collected from January 2008 to January 2009,which included 53 cases with HT and 57 cases with GD and 30 controls.To determinate the level of function of thyroid and the level of thyroid antibody.To determinate their serum level of CXCL10 by ELISA method.To compare their serum levels of CXCL10 among three groups.To compare the serum level of CXCL10 in HT and GD when they were patients onset,non-remission and remission and controls;To compare the serum level of CXCL10 in 24 patients with GD when they were before therapied by MMI and therapied after 3-6 months.Make relationship analysis between the level of CXCL10 and the level of FT3,FT4,sTSH,TGAb,TMAb,TRAb,TSI in GD and HT.Results:1(1) The level of serum CXCL10 in 57 patients with GD was significant higher than controls(p＜0.001).(2) The level of serum CXCL10 in 53 patients with HT was significant higher than controls(p＜0.05).(3) The level of serum CXCL10 in GD was significant higher than HT(p＜0.05).2 GD group The level of serum CXCL10 in GD when they were patients onset,non-remission was significant higher than they were remission(p＜0.001) and controls(p＜0.001).There was no difference between patients onset and non-remission(p＞0.05).There was no difference between patients remission and controls(p＞0.05).The level of serum CXCL10 in 24 patients with GD before they therapied was significant higher than they were therapied by MMI after 3-6 months (p＜0.001).In GD group there was positive correlation between CXCL10 and FT3,FT4;there was no correlation between CXCL10 and TSH;there was no correlation in GD group between CXCL10 and TGAb,TMAb,TRAb,there was positive correlation between CXCL10 and TSI(p＜0.05).3 HT group The level of serum CXCL10 in HT when they were patients onset was significant higher than they were remission and controls(p＜0.001).The level of serum CXCL10 in HT when they were patients non-remission was significant higher than they were remission and controls(p＜0.05).There was no difference between patients onset and non-remission(p＞0.05).There was no difference between patients remission and controls(p＞0.05).In HT group there was positive correlation between CXCL10 and sTSH(p＜0.01),there was no correlation between CXCL10 and FT3,FT4(p＞0.05);there was no correlation between CXCL10 and TGAb,TMAb,TRAb,TSI(p＞0.05).Conclusion:1 The level of serum chemokines CXCL10 in children AITD was higher than controls, so this study supporting that chemokines CXCL10 may participate in the immunoregulation of children AITD when they were invasion and development.2 The circulating concentrations of CXCL10 have been found to be increased in GD and HT when they were initial stage and relapses,and they have been found to be decreased in AITD when they were remission.CXCL10 play an important role in the initial stage of children with AITD.,and there was close correlation between CXCL10 and the severity degree of disease.So CXCL10 may be as one of index to predict the reactiveness of disease.